JP2007513079A5 - - Google Patents

Download PDF

Info

Publication number
JP2007513079A5
JP2007513079A5 JP2006539072A JP2006539072A JP2007513079A5 JP 2007513079 A5 JP2007513079 A5 JP 2007513079A5 JP 2006539072 A JP2006539072 A JP 2006539072A JP 2006539072 A JP2006539072 A JP 2006539072A JP 2007513079 A5 JP2007513079 A5 JP 2007513079A5
Authority
JP
Japan
Prior art keywords
disease
copolymer
iii
pharmaceutical composition
neurodegenerative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2006539072A
Other languages
English (en)
Japanese (ja)
Other versions
JP2007513079A (ja
JP5456235B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IL2004/001037 external-priority patent/WO2005046719A1/en
Publication of JP2007513079A publication Critical patent/JP2007513079A/ja
Publication of JP2007513079A5 publication Critical patent/JP2007513079A5/ja
Application granted granted Critical
Publication of JP5456235B2 publication Critical patent/JP5456235B2/ja
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

JP2006539072A 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法 Expired - Fee Related JP5456235B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US51862703P 2003-11-12 2003-11-12
US60/518,627 2003-11-12
US61096604P 2004-09-20 2004-09-20
US60/610,966 2004-09-20
PCT/IL2004/001037 WO2005046719A1 (en) 2003-11-12 2004-11-11 Vaccine and method for treatment of neurodegenerative diseases

Publications (3)

Publication Number Publication Date
JP2007513079A JP2007513079A (ja) 2007-05-24
JP2007513079A5 true JP2007513079A5 (cg-RX-API-DMAC7.html) 2008-01-10
JP5456235B2 JP5456235B2 (ja) 2014-03-26

Family

ID=34594916

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2006539072A Expired - Fee Related JP5456235B2 (ja) 2003-11-12 2004-11-11 神経変性疾患を治療するためのワクチン及び方法

Country Status (7)

Country Link
US (3) US20080085269A1 (cg-RX-API-DMAC7.html)
EP (2) EP1684797A1 (cg-RX-API-DMAC7.html)
JP (1) JP5456235B2 (cg-RX-API-DMAC7.html)
AU (1) AU2004288654B2 (cg-RX-API-DMAC7.html)
CA (1) CA2546077C (cg-RX-API-DMAC7.html)
IL (2) IL175535A (cg-RX-API-DMAC7.html)
WO (1) WO2005046719A1 (cg-RX-API-DMAC7.html)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
DK1701730T3 (da) * 2003-12-09 2013-11-25 Yeda Res & Dev Fremgangsmåde og vaccine omfattende copolymer 1 til behandling af psykiatriske forstyrrelser
WO2009040814A1 (en) 2007-09-24 2009-04-02 Hadasit Medical Research Services & Development Ltd Use of copolymer 1 for treatment of muscular dystrophy
WO2010019270A1 (en) * 2008-08-14 2010-02-18 Isis Pharmaceuticals, Inc. Modulation of prion expression
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EA025780B1 (ru) 2010-10-11 2017-01-30 Тева Фармасьютикал Индастриз Лтд. Цитокиновые биомаркеры в качестве биомаркеров, прогнозирующих клинический ответ на глатирамер ацетат
ES2601892T3 (es) 2011-04-21 2017-02-16 Mapi Pharma Limited Pentapolímero aleatorio para el tratamiento de enfermedades autoinmunes
MX2014004309A (es) 2011-10-10 2015-07-06 Teva Pharma Polimorfismos de nucleotidos individuales utiles para predecir una respuesta clinica para el acetato de glatiramer.
WO2013059322A2 (en) * 2011-10-17 2013-04-25 Lawrence Steinman Amyloid beta peptide as a therapy for inflammation
EP3027205A4 (en) 2013-07-28 2017-07-19 Qantu Therapeutics, Inc. Vaccine formulations that induce a th2 immune response
US10519237B2 (en) 2014-03-12 2019-12-31 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
US10618963B2 (en) 2014-03-12 2020-04-14 Yeda Research And Development Co. Ltd Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS
KR20200029627A (ko) * 2014-03-12 2020-03-18 예다 리서치 앤드 디벨럽먼트 캄파니 리미티드 Cns의 질환 및 손상을 치료하기 위한 전신적 조절 t 세포 수준 또는 활성의 감소
US11058720B2 (en) * 2016-05-20 2021-07-13 Cedars-Sinai Medical Center Methods of treating or preventing alzheimer's disease and associated conditions
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
IL316573A (en) 2017-03-26 2024-12-01 Mapi Pharma Ltd Storage systems containing glatiramer acetate for the treatment of multiple sclerosis
US12281305B2 (en) 2018-11-21 2025-04-22 Ionis Pharmaceuticals, Inc. Compounds and methods for reducing prion expression
EP3725370A1 (en) 2019-04-19 2020-10-21 ImmunoBrain Checkpoint, Inc. Modified anti-pd-l1 antibodies and methods and uses for treating a neurodegenerative disease

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US6071970A (en) * 1993-02-08 2000-06-06 Nps Pharmaceuticals, Inc. Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases
IL113812A (en) 1994-05-24 2000-06-29 Yeda Res & Dev Copolymer-1 pharmaceutical compositions containing it and its use
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US6794414B1 (en) * 1998-06-17 2004-09-21 Yeda Research And Development Co. Ltd. Method and compositions for treating diseases mediated by transglutaminase activity
EP1098902A4 (en) 1998-07-23 2002-07-24 Yeda Res & Dev TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES
JP2003521448A (ja) 1998-07-23 2003-07-15 ザ・プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ 合成ペプチドおよび自己免疫疾患治療のための使用方法
HK1054507B (zh) * 2000-01-20 2008-10-31 耶达研究及发展有限公司 共聚物1和相关肽和多肽及其处理过的t细胞在神经保护性治疗中的用途
DE60116467T2 (de) * 2000-06-07 2006-11-02 Yeda Research And Development Co., Ltd. Verwendung des Copolymer-1 Peptids sowie von damit verwandten Peptiden und Polypeptiden und von damit behandelten T-Zellen zur Neuroprotektion gegen die Toxizität von Glutamat
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
ES2387082T3 (es) * 2001-05-17 2012-09-13 Merck Serono Sa Uso de OSTEOPONTINA para el tratamiento y/o prevención de enfermedades neurológicas
US7718699B1 (en) * 2005-03-04 2010-05-18 Broyles Robert H Abscissic acid and derivatives thereof for the treatment of diseases
US7351686B2 (en) 2001-12-06 2008-04-01 Yeda Research And Development Co. Ltd. Method for neuronal protection in amyotrophic lateral sclerosis by a vaccine comprising Copolymer-1 or Copolymer-1 related peptides
CA2546077C (en) 2003-11-12 2016-07-05 Yeda Research And Development Co. Ltd. Vaccine and method for treatment of neurodegenerative diseases
US7220729B2 (en) * 2004-05-10 2007-05-22 Academia Sinica Huntington's Disease Treatment

Similar Documents

Publication Publication Date Title
BRPI0517227B8 (pt) comprimido oral de liberação prolongada do ácido 1-{[alfa-isobutanoiloxietoxi)carbonil]amino metil}-1-cicloexano acético, e, uso do comprimido
IL222880A (en) Peptides and their use in the treatment and diagnosis of diseases and pharmaceutical preparations containing them
JP2017164557A (ja) 経鼻配送装置
BRPI0513959A (pt) anticorpos dirigidos contra o peptìdeo beta-amilóide, suas composições farmacêuticas, kit e métodos de fabricação dos mesmos
EP2301569A3 (en) Vaccine and method for treatment of neurodegenerative diseases
JP2008538564A5 (cg-RX-API-DMAC7.html)
EA200800007A1 (ru) Фармацевтические композиции на основе нейроактивного стероида и их применение
JP2007538008A5 (cg-RX-API-DMAC7.html)
ATE461941T1 (de) Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation
EP2679235A3 (en) Peptides and related molecules that modulate nerve growth factor activity
EP2325209A3 (en) Improved protofibril selective antibodies and the use thereof
HRP20150237T1 (hr) Pegilirani fab protiv amiloida-beta
WO2010115843A3 (en) Pharmaceutical composition
WO2004078777A3 (en) Dipeptidyl-peptidase protected proteins
JP2011518179A5 (cg-RX-API-DMAC7.html)
US20210401751A1 (en) Compositions for treating viral infections and methods for same
JP2019537582A5 (cg-RX-API-DMAC7.html)
CN110799522A (zh) 用于治疗、改善或预防脑出血的肽及其用途
SE0402345D0 (sv) A metered medication dose
ATE442158T1 (de) Oral verabreichte pharmazeutische zusammensetzungen mit einem abgabemittel in mikronisierter form
WO2007145589A8 (en) Peptides that are capable of binding to amyloid-beta peptide.
WO2006052821A3 (en) Compositions and methods for treatment of protein misfolding and protein aggregation diseases
WO2007021886A3 (en) Truncated memapsin 2 for use for treating alzheimer's disease
DK1969003T3 (da) Anvendelser af et neurotrofisk faktor-protein
JP2009500045A5 (cg-RX-API-DMAC7.html)